Conference/Events
| ShowHide Related Items >><< AFG American Financial Group - 01/27/21
- American Financial Group to sell Annuity business to MassMutual for $3.5B
- 01/27/21
- American Financial Group to sell Annuity business to MassMutual for $3.5B
- 12/09/20
- American Financial Group declares special dividend of $2.00 per share
- 09/28/20
- American Financial Group to sell GAI Holding Bermuda to RiverStone
- 02/18/21
- Apollo Global appoints Jay Clayton as Lead Independent Director
- 02/16/21
- Apollo Global, Athene Holding to sell AmeriHome Mortgage to Western Alliance
- 02/16/21
- Apollo Global closes on $2.34B in commitments for Apollo Accord Fund IV
- 02/09/21
- Intrado announces launch of Emergency Data Broker
- 02/17/21
- Brown & Brown names Gray Nester as Chief Information Officer
- 01/04/21
- Brown & Brown acquires ADM Marketing Group, ADM Insurance Services
- 01/04/21
- Brown & Brown acquires Berry Insurance Group, terms not disclosed
- 12/21/20
- Brown & Brown gets certificate of occupancy from Daytona Beach for headquarters
- 02/24/21
- Popular VP Gilberto Monzon sells over $325K in shares
- 10/28/20
- Popular implements branch realignment in New York metro region
- 01/12/21
- EverQuote announces promotion of David Brainard to CTO
- 01/06/21
- EverQuote appoints Craig Lister as CMO
- 11/29/20
- EverQuote announces sudden passing of co-founder, CEO Seth Birnbaum
- 11/10/20
- EverQuote promotes Nick Graham to Marketplace chief revenue officer
- 02/11/21
- Sculptor Capital rises 11.4%
- 02/18/21
- State Street appoints Theresa McLaughlin as global CMO
- 01/20/21
- State Street to eliminate 1,200 positions this year
- 01/19/21
- State Street sees Q1 NII down about 68% sequentially
- 01/19/21
- State Street sees Q1 fee revenue down y/y by low single digits
- 02/25/21
- Sallie Mae increases price range, extends expiration to buy up to $1B in stock
- 01/26/21
- Sallie Mae names Kerri Palmer Chief Risk and Compliance Officer
- 02/19/21
- Goldman Sachs CFO sells 20K shares of common stock
- 02/02/21
- Goldman Sachs officer Laurence Stein sold almost $3M in company shares
- 02/01/21
- Northrop Grumman announces $2B accelerated share repurchase program
- 01/19/21
- Goldman Sachs: Investment banking backlog at near-record levels
- 12/17/20
- The Hartford authorizes $1.5B share buyback
- 02/18/21
- Verisk Analytics appoints Kathy Card Beckles as general counsel
- 02/16/21
- Berkshire Hathaway buys Verizon, exits Barrick Gold in Q4
- 02/16/21
- Buffett's Berkshire Hathaway reports no longer holding JPMorgan
- 02/16/21
- JPMorgan reports January net credit loss 1.97% vs. 2.19% last year
- 02/08/21
- Elevate Credit not guiding FY21 due to COVID uncertainty
- 02/08/21
- Elevate Credit board authorized $25M increase to existing share buyback program
- 10/14/20
- Elevate Credit promotes Scott Greever to chief product officer
- 02/16/21
- Cooperman's Omega Advisors buys GM, exits Lee in Q4
- 12/07/20
- Mr. Cooper says certain legacy regulatory matters with CFPB, state AGs resolved
- 11/16/20
- Omega takes Alphabet Class A stake, exits position in JPMorgan
- 09/04/20
- Etsy, Teradyne, Catalent to join S&P 500
- 02/23/21
- CME Group Kometer sells almost $1.6M in shares
- 02/08/21
- CME Group announces launch of Ether futures
- 02/02/21
- CME Group reached ADV of 19.2M contracts in January
- 01/26/21
- CME Group to launch Global Emissions Offset contract on March 1
- 12/28/20
- FirstCash appoints Paula Garrett to board of directors
- 10/21/20
- FirstCash declares 27c per share quarterly dividend for Q4
- 10/21/20
- FirstCash lifts temporary suspension of share repurchase program
- 10/21/20
- FirstCash sees smaller percentage decline in pawn fees in Q4
- 02/16/21
- Cboe to enable electronic auction mechanism for S&P 500 index options
- 02/08/21
- ETFS Capital acquires ETF.com from Cboe Global Markets, terms not disclosed
- 01/25/21
- Cboe Global Markets announces plan for new incentive program
- 01/14/21
- Cboe Global Markets PAC temporarily pausing all donations
- 01/28/21
- Selective Insurance sees FY21 GAAP combined ratio, ex-catastrophe losses, 91%
- 12/02/20
- Selective Insurance announces new $100M share repurchase program
- 02/23/21
- Wells Fargo confirms sale of WFAM to GTCR, Reverence Capital for $2.1B
- 02/23/21
- Wells Fargo enters pact with GTCR, Reverence Capital to sell WFAM for $2.1B
- 02/17/21
- Wells Fargo up 5% after Bloomberg report points to progress with Fed
- 02/16/21
- Berkshire Hathaway buys Verizon, exits Barrick Gold in Q4
- 01/28/21
- WisdomTree launches Cybersecurity Fund
- 01/27/21
- WisdomTree appoints Smita Conjeevaram to board of directors
- 10/20/20
- WisdomTree, 55ip collaborate for tax-smart WisdomTree model portfolios
- 02/04/21
- Tradeweb Markets reports $20T total volume traded in January
- 02/04/21
- Tradeweb Markets sees FY21 CapEx $45M-$50M
- 02/02/21
- Tradeweb Markets to acquire Nasdaq fixed income trade platform for $190M
- 02/02/21
- Nasdaq to sell U.S. fixed income business to Tradeweb Markets
- $694.55 /
-17.965 (-2.52%) - 02/24/21
- Berkshire Grey to combine with Revolution Acceleration Acquisition Corp
- 02/22/21
- GasLog announces take private transaction with BlackRock's GEPIF team
- 02/09/21
- Green Plains announces strategic transactions with BlackRock
- 02/04/21
- BlackRock CEO sells 27.4K shares of common stock
- 02/16/21
- Amundi US appoints BNY Mellon as fund service provider
- 02/11/21
- BNY Mellon announces formation of new digital assets unit
- 01/19/21
- BNY Mellon to implement data management platform for Janus Henderson
- 01/13/21
- BNY Mellon, Amundi announce strategic alliance
- 02/21/21
- Fly Intel: Top five weekend stock stories
- 02/16/21
- Berkshire Hathaway buys Verizon, exits Barrick Gold in Q4
- 02/16/21
- Bank of America reports January net charge-offs 1.75% vs. 2.49% last year
- 02/11/21
- Bank of America targets net zero greenhouse gas emissions before 2050
AFG American Financial Group - 02/22/21 Piper Sandler
- American Financial Group price target raised to $125 from $110 at Piper Sandler
- 01/28/21 Credit Suisse
- American Financial Group price target raised to $110 from $95.75 at Credit Suisse
- 09/30/20 Credit Suisse
- American Financial Group initiated with an Outperform at Credit Suisse
- 08/13/20 Raymond James
- American Financial Group upgraded at Raymond James on better outlook visibility
ALAB Alabama National Bancorp - 01/20/21 Truist
- Athene Holding price target raised to $55 from $48 at Truist
- 01/11/21 Wells Fargo
- Apollo Global price target raised to $55 from $50 at Wells Fargo
- 12/18/20 Deutsche Bank
- Apollo Global price target raised to $51 from $49 at Deutsche Bank
- 11/06/20
- Fly Intel: Top five analyst upgrades
- 01/18/21 Keefe Bruyette
- Brown & Brown upgraded to Outperform from Market Perform at Keefe Bruyette
- 01/15/21 Deutsche Bank
- Brown & Brown named 'Catalyst Call: Buy Idea' at Deutsche Bank
- 01/08/21 Goldman Sachs
- Brown & Brown upgraded to Buy from Neutral at Goldman Sachs
- 12/31/20 Credit Suisse
- Brown & Brown price target raised to $50 from $47 at Credit Suisse
- 01/29/21 RBC Capital
- Popular price target raised to $70 from $48 at RBC Capital
- 01/08/21 UBS
- Popular upgraded to Buy from Neutral at UBS
- 09/22/20
- Top five analyst initiations
- 09/22/20 UBS
- Popular initiated with a Neutral at UBS
- 02/23/21 Oppenheimer
- EverQuote price target raised to $70 from $55 at Oppenheimer
- 12/16/20 JPMorgan
- EverQuote price target lowered to $48 from $54 at JPMorgan
- 11/03/20 Raymond James
- EverQuote price target lowered to $51 from $63 at Raymond James
- 11/03/20 JPMorgan
- EverQuote price target lowered to $54 from $60 at JPMorgan
- 12/18/20 Citi
- Citi opens '90-Day Catalyst Watch' on Sculptor Capital
- 12/16/20 Citi
- Sculptor Capital price target raised to $26.50 from $25 at Citi
- 09/29/20 Citi
- Citi opens '90-Day Positive Catalyst Watch' on Sculptor Capital
- 07/24/20 Citi
- Citi boosts Sculptor Capital target, opens 'Positive Catalyst Watch'
- 01/21/21 Wells Fargo
- State Street price target raised to $83 from $75 at Wells Fargo
- 01/20/21 RBC Capital
- State Street price target raised to $86 from $78 at RBC Capital
- 01/11/21 Piper Sandler
- State Street price target raised to $81 from $69 at Piper Sandler
- 01/05/21 Wolfe Research
- State Street downgraded to Underperform from Peer Perform at Wolfe Research
- 01/29/21 Barclays
- Sallie Mae price target raised to $18 from $15 at Barclays
- 01/29/21 RBC Capital
- Sallie Mae upgraded to Outperform from Sector Perform at RBC Capital
- 01/29/21 Citi
- Sallie Mae price target raised to $16 from $12 at Citi
- 01/29/21 RBC Capital
- Sallie Mae upgraded to Outperform from Sector Perform at RBC Capital
- 02/19/21 Keefe Bruyette
- Focus Financial price target raised to $61 from $54 at Keefe Bruyette
- 08/04/20 Truist
- Focus Financial price target raised to $50 from $30 at Truist
- 06/30/20 Goldman Sachs
- Focus Financial upgraded to Buy from Neutral at Goldman Sachs
- 06/22/20 Credit Suisse
- Focus Financial Partners initiated with an Outperform at Credit Suisse
- 02/24/21 Wells Fargo
- Goldman Sachs price target raised to $360 from $335 at Wells Fargo
- 01/28/21 Deutsche Bank
- Goldman Sachs price target raised to $310 from $290 at Deutsche Bank
- 01/22/21 Citi
- Goldman Sachs price target raised to $370 from $357 at Citi
- 01/20/21 Credit Suisse
- Goldman Sachs price target raised to $345 from $325 at Credit Suisse
- 02/19/21 Raymond James
- Hartford Financial initiated with an Outperform at Raymond James
- 02/18/21 Raymond James
- Hartford Financial initiated with an Outperform at Raymond James
- 02/08/21 RBC Capital
- Hartford Financial price target raised to $51 from $43 at RBC Capital
- 01/04/21 JPMorgan
- Hartford Financial upgraded to Overweight with $55 target at JPMorgan
- 01/19/21 DA Davidson
- JPMorgan price target raised to $163 from $147 at DA Davidson
- 01/19/21 Seaport Global
- JPMorgan price target raised to $157 from $140 at Seaport Global
- 01/19/21 RBC Capital
- JPMorgan price target raised to $150 from $130 at RBC Capital
- 01/19/21 Credit Suisse
- JPMorgan price target raised to $150 from $142 at Credit Suisse
- 04/14/20 Maxim
- LendingClub, Enova International, Elevate Credit cut to Hold at Maxim
- 04/14/20 Maxim
- Elevate Credit downgraded to Hold from Buy at Maxim
- 02/24/21 Credit Suisse
- Mr. Cooper price target raised to $40 from $34 at Credit Suisse
- 12/14/20 Jefferies
- Mr. Cooper initiated with a Hold at Jefferies
- 12/10/20 Barclays
- Mr. Cooper price target raised to $38 from $28 at Barclays
- 11/30/20 Wedbush
- Mr. Cooper price target raised to $34 from $27.50 at Wedbush
- 02/25/21 Wells Fargo
- CME Group upgraded to Overweight at Wells Fargo
- 02/25/21 Wells Fargo
- CME Group upgraded to Overweight from Equal Weight at Wells Fargo
- 02/11/21 Citi
- CME Group price target lowered to $207 from $210 at Citi
- 01/15/21 Oppenheimer
- CME Group downgraded to Perform on valuation at Oppenheimer
- 09/03/20 Credit Suisse
- Credit Suisse upgrades FirstCash ahead of expected earnings recovery
- 09/03/20 Credit Suisse
- FirstCash upgraded to Outperform from Neutral at Credit Suisse
- 08/12/20 Barclays
- FirstCash upgraded to Overweight ahead of expected 2H recovery at Barclays
- 08/12/20 Barclays
- FirstCash upgraded to Overweight from Equal Weight at Barclays
- 02/08/21 Deutsche Bank
- Cboe Global Markets price target lowered to $103 from $108 at Deutsche Bank
- 01/07/21 Wells Fargo
- Cboe Global Markets price target raised to $110 from $105 at Wells Fargo
- 01/07/21 JPMorgan
- Cboe downgraded to Underweight with $93 target at JPMorgan
- 01/07/21 JPMorgan
- Cboe Global Markets downgraded to Underweight from Neutral at JPMorgan
- 11/10/20 Credit Suisse
- Selective Insurance price target raised to $71 from $66 at Credit Suisse
- 05/14/20 Credit Suisse
- Selective Insurance upgraded to Outperform from Underperform at Credit Suisse
- 03/09/20 JMP Securities
- Selective Insurance upgraded to Outperform at JMP Securities
- 02/18/21
- Fly Intel: Top five analyst upgrades
- 02/18/21 JPMorgan
- Wells Fargo upgraded to Neutral with cap lift closer at JPMorgan
- 02/18/21 JPMorgan
- Wells Fargo upgraded to Neutral from Underweight at JPMorgan
- 02/17/21 Goldman Sachs
- Goldman says Fed approving Wells' risk overhaul plan would be 'important step'
- 02/01/21 Deutsche Bank
- WisdomTree price target raised to $6 from $5 at Deutsche Bank
- 01/11/21 Morgan Stanley
- WisdomTree downgraded to Underweight after 50% rally at Morgan Stanley
- 01/11/21 Morgan Stanley
- WisdomTree downgraded to Underweight from Equal Weight at Morgan Stanley
- 12/29/20 Northland
- WisdomTree price target raised to $6 from $4.25 at Northland
- 12/18/20 Keefe Bruyette
- Two Harbors downgraded to Market Perform from Outperform at Keefe Bruyette
- 12/14/20 Jefferies
- Two Harbors initiated with a Hold at Jefferies
- 12/10/20 Barclays
- Two Harbors downgraded to Equal Weight from Overweight at Barclays
- 11/24/20 Raymond James
- Two Harbors downgraded to Market Perform from Outperform at Raymond James
- 02/22/21 Goldman Sachs
- Tradeweb Markets upgraded to Buy from Neutral at Goldman Sachs
- 01/13/21 Compass Point
- Tradeweb Markets upgraded in relative call against MarketAxess at Compass Point
- 01/13/21 Compass Point
- Tradeweb Markets upgraded to Buy from Neutral at Compass Point
- 09/14/20 Rosenblatt
- Tradeweb Markets upgraded to Buy from Neutral at Rosenblatt
- $694.55 /
-17.965 (-2.52%) - 02/22/21 Stifel
- GasLog downgraded to Hold from Buy at Stifel
- 01/19/21 RBC Capital
- PNC Financial price target raised to $161 from $135 at RBC Capital
- 01/15/21 BMO Capital
- BlackRock price target raised to $715 from $709 at BMO Capital
- 01/15/21 Deutsche Bank
- BlackRock price target raised to $838 from $835 at Deutsche Bank
- 01/21/21 RBC Capital
- BNY Mellon price target raised to $49 from $43 at RBC Capital
- 01/21/21 Citi
- BNY Mellon earnings selloff a 'bit overdone,' says Citi
- 01/11/21 Citi
- BNY Mellon upgraded to Buy from Neutral at Citi
- 01/11/21 Citi
- BNY Mellon upgraded to Buy from Neutral at Citi
- 02/22/21 Wells Fargo
- Wells Fargo boosts Bank of America target, sees path to $55 per share
- 01/26/21 Atlantic Equities
- Bank of America upgraded to Overweight from Neutral at Atlantic Equities
- 01/20/21 RBC Capital
- Bank of America price target raised to $37 from $28 at RBC Capital
- 01/11/21 Citi
- Bank of America upgraded to Buy from Neutral at Citi
AFG American Financial Group - 02/03/21
- American Financial Group reports Q4 EPS $2.25, consensus $2.13
- 10/28/20
- American Financial reports Q3 core EPS $2.45, consensus $1.71
- 02/03/21
- Apollo Global reports Q4 fee related EPS 63c, consensus 50c
- 02/02/21
- Notable companies reporting before tomorrow's open
- 02/02/21
- Notable companies reporting before tomorrow's open
- 10/29/20
- Apollo Global reports Q3 fee-related EPS 63c, consensus 49c
- 01/25/21
- Brown & Brown reports Q4 adjusted EPS 32c, consensus 29c
- 10/26/20
- Brown & Brown reports Q3 EPS 52c, consensus 43c
- 01/28/21
- Popular reports Q4 EPS $2.10, consensus $1.54
- 10/28/20
- Popular reports Q3 EPS $2.00, consensus $1.20
- 02/22/21
- EverQuote sees FY21 revenue of $430M - $440M, consensus $415.34
- 02/22/21
- EverQuote sees Q1 revenue $102M-$102M, consensus $100.07M
- 02/22/21
- EverQuote reports Q4 EPS (13c), consensus (15c)
- 11/02/20
- EverQuote reports Q3 EPS(12c) , consensus (7c)
- 01/19/21
- State Street reports Q4 EPS $1.39, consensus $1.56
- 10/16/20
- State Street reports Q3 EPS $1.45, consensus $1.41
- 10/15/20
- Notable companies reporting before tomorrow's open
- 10/15/20
- Notable companies reporting before tomorrow's open
- 01/27/21
- Sallie Mae reports Q4 core EPS $1.15, consensus 35c
- 01/27/21
- Notable companies reporting after market close
- 10/21/20
- Sallie Mae reports Q3 core EPS 47c, consensus 8c
- 10/21/20
- Notable companies reporting after market close
- 02/18/21
- Focus Financial reports Q4 adjusted EPS with tax adjustments 84c, consensus 76c
- 11/05/20
- Focus Financial reports Q3 EPS 75c including tax adjustments, consensus 72c
- 11/05/20
- Focus Financial reports Q3 adj. EPS 63c, consensus 72c
- 01/19/21
- Goldman Sachs reports Q4 EPS $12.08, consensus $7.47
- 01/18/21
- Fly Intel: What to watch in next round of big banks' earnings reports
- 10/14/20
- Goldman Sachs reports Q3 EPS $9.68, consensus $5.57
- 10/13/20
- Notable companies reporting before tomorrow's open
- 02/04/21
- Hartford Financial reports Q4 core EPS $1.76, consensus $1.33
- 02/04/21
- Notable companies reporting after market close
- 10/29/20
- Hartford Financial reports Q3 core EPS $1.46, consensus 90c
- 10/29/20
- Notable companies reporting after market close
- 01/15/21
- JPMorgan reports Q4 EPS $3.79, consensus $2.62
- 01/14/21
- Notable companies reporting before tomorrow's open
- 01/14/21
- Notable companies reporting before tomorrow's open
- 01/14/21
- Fly Intel: What to watch in first round of big bank earnings reports
- 02/08/21
- Elevate Credit reports Q4 EPS 23c, consensus 20c
- 11/09/20
- Elevate Credit reports Q3 adjusted EPS 42c, consensus 17c
- 02/23/21
- Mr. Cooper reports Q4 EPS $2.00, consensus $2.38
- 02/10/21
- CME Group reports Q4 adjusted EPS $1.39, consensus $1.36
- 02/09/21
- Notable companies reporting before tomorrow's open
- 02/09/21
- Notable companies reporting before tomorrow's open
- 10/28/20
- CME Group reports Q3 adjusted EPS $1.38, consensus $1.41
- 01/28/21
- FirstCash reports Q4 non-GAAP EPS 84c, consensus 81c
- 10/21/20
- FirstCash reports Q3 adjusted EPS 59c, consensus 49c
- 02/05/21
- Cboe Global Markets sees 2021 organic revenue growth 4%-6%, consensus $1.26B
- 02/05/21
- Cboe Global Markets reports Q4 adjusted EPS $1.21, consensus $1.23
- 02/03/21
- Cboe Global Markets reports total January options ADV up 48.1% y/o/y
- 10/30/20
- Cboe Global Markets reports Q3 adjusted EPS $1.11, consensus $1.06
- 01/28/21
- Selective Insurance reports Q4 adjusted EPS $1.84, consensus $1.20
- 10/28/20
- Selective Insurance reports Q3 adjusted EPS $1.06, consensus $1.07
- 01/15/21
- Wells Fargo reports Q4 EPS 64c, consensus 60c
- 01/14/21
- Notable companies reporting before tomorrow's open
- 01/14/21
- Notable companies reporting before tomorrow's open
- 01/14/21
- Fly Intel: What to watch in first round of big bank earnings reports
- 01/29/21
- WisdomTree reports Q4 adjusted EPS 6c, consensus 5c
- 10/30/20
- WisdomTree reports Q3 adj. EPS 7c, consensus 5c
- 02/09/21
- Two Harbors reports Q4 core EPS 30c, consensus 23c
- 11/04/20
- Two Harbors reports Q3 EPS 28c, consensus 24c
- 02/04/21
- Tradeweb Markets reports Q4 adjusted EPS 34c, consensus 34c
- 10/28/20
- Tradeweb Markets reports Q3 EPS 30c, consensus 29c
- $694.55 /
-17.965 (-2.52%) - 01/14/21
- BlackRock reports Q4 adjusted EPS $10.18, consensus $9.14
- 01/13/21
- Notable companies reporting before tomorrow's open
- 10/13/20
- BlackRock reports Q3 adjusted EPS $9.22, consensus $7.77
- 10/12/20
- Notable companies reporting before tomorrow's open
- 01/20/21
- BNY Mellon reports Q4 ex-items EPS 96c, consensus 91c
- 01/19/21
- Notable companies reporting before tomorrow's open
- 01/19/21
- Notable companies reporting before tomorrow's open
- 10/16/20
- BNY Mellon reports Q3 EPS 98c, consensus 94c
- 01/19/21
- Bank of America reports Q4 EPS 59c, consensus 55c
- 01/18/21
- Fly Intel: What to watch in next round of big banks' earnings reports
- 10/14/20
- Bank of America reports deposits rose $320B, or 23%, to $1.7T
- 10/14/20
- Bank of America reports Q3 EPS 51c, consensus 49c
|
Conference/Events
| ShowHide Related Items >><< ACRS Aclaris Therapeutics - 02/25/21
- Aclaris Therapeutics sees cash, equivalents funding operations through 2023E
- 02/22/21
- Aclaris Therapeutics trading resumes
- 02/22/21
- Aclaris Therapeutics trading halted, volatility trading pause
- 01/21/21
- Aclaris gets orphan drug designation in cryopyrin-associated periodic syndrome
- $65.26 /
-2.3001 (-3.40%) - 02/19/21
- BridgeBio, ML Bio Solutions dose first patient in Phase 2 trial of BBP-418
- 02/02/21
- BridgeBio doses first patient in Phase 1/2 trial of BBP-681 for malformations
- 01/26/21
- BridgeBio completes acquisition of Eidos Therapeutics
- 01/19/21
- BridgeBio and Eidos' stockholders approve acquisition
- 01/21/21
- Helios Technologies to acquire BJN Technologies, terms undisclosed
- 10/12/20
- Helios Technologies to acquire Balboa Water Group for $218.5M
- 02/16/21
- Metracrine announces publication of results from Phase 1b study of MET409
- 01/19/21
- Metracrine's MET642 granted Fast Track designation by FDA
- 01/05/21
- Metracrine treats first patient in Phase 2a trial of MET409 with Jardiance
- 12/17/20
- Metracrine's MET642 reports positive efficacy and safety Phase 1 results
- 11/23/20
- Sientra receives approval for Sientra OPUS silicone gel breast implant sizer
- 11/09/20
- Sientra names Ron Menezes CEO, Jeffrey Nugent to retire
- 02/01/21
- Trevi Therapeutics appoints William Forbes as Chief Development Officer
- 10/21/20
- Trevi Therapeutics resumes patient screening for Phase 2 trial of Haduvio
- 02/03/21
- Veracyte to acquire Decipher Biosciences for $600M
- 12/22/20
- Bayer, Veracyte announce new collaboration to advance precision oncology
- 12/21/20
- Veracyte receives ISO certification for QMS
- 12/15/20
- Veracyte announces expansion of collaboration of lung cancer initiative at JNJ
- 02/24/21
- Vincera Pharma to host KOL webinar on VIP152
- 01/07/21
- Vincera Pharma changes name to Vincerx
- 12/23/20
- Vincera Pharma comples business combination with LifeSci Acquisition
- 01/19/21
- CytoSorb approved in Korea for all EU approved indications
- 01/12/21
- Health Canada authorizes CytoSorb for use in hospitalized COVID-19 patients
- 01/04/21
- CytoSorbents gets Medical Device Authorization for CytoSorb in COVID-19 patients
- 12/09/20
- CytoSorbents announces publication of CytoSorb matched analysis
- 02/16/21
- Moderna provides supply update for U.S. COVID-19 vaccines
- 02/02/21
- Catalent reports Q2 adjusted EPS 63c, consensus 55c
- 01/13/21
- Catalent to acquire manufacturing operations from Acorda Therapeutics
- 01/13/21
- Acorda to sell Inbrija manufacturing operations to Catalent for $80M
- 01/20/21
- Imara appoints Kenneth Atttie as Chief Medical Officer
- 01/06/21
- Imara reports Phase 2a trial results of IMR-687 in SCD
- 12/07/20
- Imara presents IMR-687 Phase 2a OLE case reports
- 11/30/20
- Imara to present clinical data on IMR-687 at ASH Annual Meeting
- 11/12/20
- iTeos Therapeutics appoints Matthew Roden to board of directors
- $203.91 /
-0.735 (-0.36%) - 02/25/21
- Eli Lilly, Welldoc announce agreement to create insulin management solution
- 02/23/21
- Veru submits NDA for proprietary TADFIN for BPH
- 02/18/21
- Eli Lilly, Rigel Pharmaceuticals enter exclusive license agreement for R552
- 02/17/21
- Eli Lilly announces SURPASS-3, SURPASS-5 trials meet primary endpoints
AUPH Aurinia Pharmaceuticals - 01/24/21
- FDA approves Aurinia's LUPKYNIS for adult patients with active lupus nephritis
- 01/22/21
- Aurinia Pharmaceuticals trading halted, news pending
- 12/17/20
- Aurinia Pharmaceuticals enters voclosporin license agreement with Otsuka
- 12/15/20
- Aurinia, Lonza strike exclusive pact for voclosporin manufacturing capacity
- 02/11/21
- Anavex sees sufficient cash runway for up to three years
- 02/04/21
- Anavex trading resumes
- 02/04/21
- Anavex trading halted, volatility trading pause
- 02/03/21
- Anavex trading resumes
- 01/27/21
- DarioHealth to acquire Upright Technologies for $29.5M in stock, $1.5M in cash
- 12/22/20
- DarioHealth enters into agreement with Presbyterian Medical Services
- 11/24/20
- DarioHealth to offer therapeutics solution to Fortune 500 technology companies
- 09/21/20
- DarioHealth, HMC HealthWorks announce partnership agreement
- $50.58 /
-1.1548 (-2.23%) - 01/08/21
- Enanta says 'meaningful progress' made on pipeline in 2020
- 09/14/20
- Enanta initiates Phase 1 clinical study of EDP-297
- 08/28/20
- Enanta to present data from hepatitis B virus, NASH programs at EASL
- 02/12/21
- Equillium presents 'positive' interim clinical data on Itolizumab trial in aGVHD
- 02/09/21
- Equillium appoints Katherine Xu to board of directors
- 12/21/20
- Equillium appoints Dolca Thomas as CMO, EVP, R&D
- 12/07/20
- Equillium presents translational data on itolizumab
- 02/25/21
- Exelixis announces Breakthrough Therapy Designation granted to cabozantinib
- 02/14/21
- Exelixis announces Phase 2 results for CABOMETYX in metastatic PRCC
- 02/12/21
- Exelixis announces 'positive' final data for Phase 1 cabozantinib trial
- 02/08/21
- Exelixis to announce results from Cabometyx retrospective analysis
- 02/25/21
- Schrodinger expands collaboration with Google Cloud
- 02/24/21
- Schrodinger holder David Shaw sells 457.7K shares of common stock
- 01/19/21
- David E Shaw reports 17.2% passive stake in Schrodinger
- 12/07/20
- Schrodinger presents data from MALT1 inhibitor program at ASH
ACRS Aclaris Therapeutics - 02/02/21 Cantor Fitzgerald
- Aclaris Therapeutics price target raised to $30 from $15 at Cantor Fitzgerald
- 01/19/21 William Blair
- Aclaris has potential in range of 'blockbuster indications,' says William Blair
- $65.26 /
-2.3001 (-3.40%) - 02/22/21 JPMorgan
- BridgeBio reinstated with an Overweight at JPMorgan
- 02/09/21
- Fly Intel: Top five analyst initiations
- 02/09/21 Goldman Sachs
- BridgeBio reinstated with a Buy at Goldman Sachs
- 01/11/21 H.C. Wainwright
- BridgeBio price target raised to $87 from $64 at H.C. Wainwright
- 10/12/20 Baird
- Helios Technologies upgraded to Outperform from Neutral at Baird
- 05/29/20 Morgan Stanley
- Morgan Stanley upgrades Helios to Equal Weight following underperformance
- 05/29/20 Morgan Stanley
- Helios Technologies upgraded to Equal Weight from Underweight at Morgan Stanley
- 03/27/20 SunTrust
- Helios Technologies price target lowered to $36 from $45 at SunTrust
- 10/12/20 Canaccord
- Metracrine initiated with a Buy at Canaccord
- 10/12/20 Jefferies
- Metracrine initiated with a Buy at Jefferies
- 10/12/20 RBC Capital
- Metracrine initiated with an Outperform at RBC Capital
- 02/05/21 Canaccord
- Sientra price target raised to $8 from $6 at Canaccord
- 10/08/20 Stifel
- Stifel sees upside potential for Sientra after survey of aesthetics doctors
- 06/11/20 Maxim
- Sientra price target raised to $8 from $5 at Maxim
- 03/12/20 Craig-Hallum
- Sientra price target lowered to $9 from $14 at Craig-Hallum
- 07/13/20 Stifel
- Trevi Therapeutics price target lowered to $10 from $14 at Stifel
- 02/18/21 Needham
- Veracyte assumed with a Buy at Needham
- 02/08/21 SVB Leerink
- Veracyte price target raised to $83 from $40 at SVB Leerink
- 01/27/21 Truist
- Veracyte initiated with a Buy at Truist
- 12/17/20 Lake Street
- Veracyte price target raised to $60 from $40 at Lake Street
- 01/06/21 Chardan
- Vincera Pharma initiated with a Buy at Chardan
- 01/04/21 B. Riley Securities
- CytoSorbents price target raised to $17 from $16 at B. Riley Securities
- 09/01/20 SVB Leerink
- CytoSorbents initiated with an Outperform at SVB Leerink
- 08/25/20 B. Riley FBR
- CytoSorbents 29% pullback from highs a buying opportunity, says B. Riley FBR
- 06/02/20 B. Riley FBR
- CytoSorbents gaining relevance as COVID-19 treatment, says B. Riley FBR
- 02/03/21 UBS
- Catalent price target raised to $135 from $115 at UBS
- 02/03/21 RBC Capital
- Catalent price target raised to $137 from $125 at RBC Capital
- 01/08/21 JPMorgan
- Catalent price target raised to $130 from $110 at JPMorgan
- 01/04/21 Stephens
- Brinker, LiveRamp and Vonage among 2021 best ideas at Stephens
- 01/06/21 SVB Leerink
- Imara selloff a potential buying opportunity, says SVB Leerink
- 08/17/20
- Fly Intel: Top five analyst upgrades
- 08/17/20 Citi
- Imara upgraded to Buy from Neutral at Citi
- 06/30/20 Citi
- Imara downgraded to Neutral from Buy at Citi
- 10/07/20 Baird
- iTeos Therapeutics initiated with an Outperform at Baird
- 09/18/20 Piper Sandler
- Piper Sandler lays out next potential takeover targets in oncology
- 09/01/20 Piper Sandler
- iTeos Therapeutics heading for 'catalyst rich stretch', says Piper Sandler
- 08/18/20 SVB Leerink
- SVB Leerink bullish on iTeos Therapeutics, initiates with an Outperform
- $203.91 /
-0.735 (-0.36%) - 02/18/21 H.C. Wainwright
- Rigel Pharmaceuticals price target raised to $11 from $8 at H.C. Wainwright
- 02/18/21 Piper Sandler
- Rigel share setup 'distinctly positive' after Lilly deal, says Piper Sandler
- 02/12/21 Cowen
- Eli Lilly price target raised to $235 from $195 at Cowen
- 02/08/21 SVB Leerink
- AbCellera price target raised to $52 from $45 at SVB Leerink
AUPH Aurinia Pharmaceuticals - 01/26/21 RBC Capital
- Aurinia Pharmaceuticals price target raised to $28 from $20 at RBC Capital
- 01/26/21 Cantor Fitzgerald
- Aurinia Pharmaceuticals price target raised to $34 from $27 at Cantor Fitzgerald
- 01/25/21 Oppenheimer
- Aurinia Pharmaceuticals price target raised to $28 from $20 at Oppenheimer
- 01/25/21 H.C. Wainwright
- Aurinia Pharmaceuticals price target raised to $35 from $30 at H.C. Wainwright
- 02/24/21 Cantor Fitzgerald
- Anavex price target raised to $25 from $10 at Cantor Fitzgerald
- 02/23/21 Cantor Fitzgerald
- Anavex price target raised to $25 from $10 at Cantor Fitzgerald
- 12/29/20 Cantor Fitzgerald
- Anavex cash position to fund operations into 2022, says Cantor Fitzgerald
- 12/16/20 H.C. Wainwright
- Anavex price target raised to $17 from $14 at H.C. Wainwright
- 02/01/21 Alliance Global Partners
- DarioHealth downgraded to Neutral from Buy at Alliance Global Partners
- 08/17/20 Aegis
- DarioHealth initiated with a Buy at Aegis
- 08/13/20 Craig-Hallum
- DarioHealth price target raised to $17 from $8 at Craig-Hallum
- 06/22/20 ThinkEquity
- DarioHealth initiated with a Buy at ThinkEquity
- $50.58 /
-1.1548 (-2.23%) - 02/09/21 RBC Capital
- Enanta price target raised to $53 from $47 at RBC Capital
- 01/29/21 JPMorgan
- Enanta upgraded to Neutral with $55 target at JPMorgan
- 01/29/21 JPMorgan
- Enanta upgraded to Neutral from Underweight at JPMorgan
- 01/08/21 Piper Sandler
- Enanta remains 'significantly undervalued,' says Piper Sandler
- 11/30/20 H.C. Wainwright
- Equillium price target lowered to $12 from $22 at H.C. Wainwright
- 07/14/20 H.C. Wainwright
- Equillium price target raised to $24 from $14 at H.C. Wainwright
- 07/10/20 Stifel
- Equillium transferred with Buy rating, $10 target at Stifel
- 02/15/21 Piper Sandler
- Exelixis price target raised to $36 from $33 at Piper Sandler
- 01/25/21 Piper Sandler
- Piper says Exelixis could have 'blockbuster opportunity' with XL102
- 01/22/21 Piper Sandler
- Exelixis combo approval came a month ahead of PDUFA, says Piper Sandler
- 01/20/21 William Blair
- Exelixis selloff on competitive concerns an 'overreaction,' says William Blair
- 01/25/21 BMO Capital
- Schrodinger price target raised to $117 from $97 at BMO Capital
- 11/23/20 BofA
- BofA upgrades Schrodinger to Buy after 'major' collaboration announcement
- 11/23/20 BofA
- Schrodinger upgraded to Buy from Neutral at BofA
- 10/12/20 Jefferies
- Schrodinger upgraded to Buy from Hold at Jefferies
ACRS Aclaris Therapeutics - 02/25/21
- Aclaris Therapeutics reports Q4 EPS (30c), consensus (27c)
- 11/04/20
- Aclaris Therapeutics reports Q3 EPS (25c), consensus (30c)
- $65.26 /
-2.3001 (-3.40%) - 02/25/21
- BridgeBio reports Q4 EPS ($1.01), consensus (85c)
- 11/05/20
- BridgeBio reports Q3 EPS (98c), consensus (92c)
- 11/02/20
- Helios Technologies sees FY20 revenue $485M-$495M, consensus $486.24M
- 11/02/20
- Helios Technologies reports Q3 adjusted EPS 53c, consensus 41c
- 11/12/20
- Metracrine reports Q3 EPS (41c), consensus ($1.41)
- 02/04/21
- Sientra reports preliminary Q4 revenue $22.6M, consensus $16.83M
- 11/09/20
- Sientra sees FY20 revenue $63M-$66M, consensus $61.31M
- 11/09/20
- Sientra reports Q3 EPS (12c), consensus (36c)
- 02/17/21
- Veracyte sees FY21 revenue $190M-$200M, consensus $151.18M
- 02/17/21
- Veracyte reports Q4 EPS (14c), consensus (11c)
- 02/03/21
- Veracyte sees FY20 revenue $117M-$118.0M, consensus $114.9M
- 02/03/21
- Veracyte sees Q4 revenue $34M-$35M, consensus $33.49M
- 11/04/20
- CytoSorbents reports Q3 EPS (2c), consensus (9c)
- 02/02/21
- Catalent raises FY21 revenue view to $3.8B-$3.95B from $3.58B-$3.78B
- 11/03/20
- Catalent raises FY21 revenue view to $3.58B-$3.78B from $3.45B-$3.6B
- 11/03/20
- Catalent reports Q1 adj. EPS 43c, consensus 37c
- 08/31/20
- Catalent sees FY21 revenue $3.45B-$3.6B, consensus $3.36B
- 11/05/20
- Imara reports Q3 EPS (72c), consensus (80c)
- 11/12/20
- iTeos Therapeutics reports Q3 EPS (48c), consensus (36c)
- 09/01/20
- iTeos Therapeutics reports Q2 EPS ($29.49) vs. ($36.49) a year ago
- $203.91 /
-0.735 (-0.36%) - 01/29/21
- Eli Lilly backs FY21 EPS view $7.75-$8.40, consensus $8.20
- 01/29/21
- Eli Lilly reports Q4 EPS $2.75, consensus $2.35
- 01/28/21
- Notable companies reporting before tomorrow's open
- 01/28/21
- Notable companies reporting before tomorrow's open
AUPH Aurinia Pharmaceuticals - 02/24/21
- Aurinia Pharmaceuticals reports Q4 EPS (5c), consensus (14c)
- 11/10/20
- Aurinia Pharmaceuticals reports Q3 EPS (28c) vs (21c) last year
- 02/11/21
- Anavex reports Q1 EPS 12c vs. 12c last year
- 12/28/20
- Anavex reports 2020 EPS (45c), consensus (48c)
- 01/27/21
- DarioHealth sees Q4 revenue $2.12M, consensus $2.15M
- 11/12/20
- DarioHealth reports Q3 EPS (71c), consensus (68c)
- $50.58 /
-1.1548 (-2.23%) - 02/08/21
- Enanta Pharmaceuticals reports Q1 EPS (41c), consensus (74c)
- 11/23/20
- Enanta reports Q4 EPS ($1.46), consensus (95c)
- 11/10/20
- Equillium reports Q3 EPS (31c), consensus (40c)
- 02/10/21
- Exelixis backs FY21 revenue view $1.15B-$1.25B, consensus $1.2B
- 02/10/21
- Exelixis reports Q4 adjusted EPS 14c, consensus 5c
- 01/10/21
- Exelixis sees FY21 revenue $1.15B-$1.25B, consensus $1.16B
- 01/10/21
- Exelixis reports preliminary Q4 revenue $270M, consensus $213.78M
- 11/12/20
- Schrodinger reports Q3 EPS 5c, consensus (7c)
|